iSTAR Medical Receives CE Mark Approval for STARflo™ Glaucoma Implant

Seattle, WA (July 3, 2012) – Healionics Corporation today announced that the company’s Belgian subsidiary, iSTAR Medical SA, has received CE Mark approval for its STARflo™ Glaucoma Implant, enabling commercialization in the European Union and Asian and Latin American countries that recognize the CE Mark.

The STARflo Glaucoma Implant is a non-degradable, precision-pore implant made from STAR® Biomaterial. It is designed to operate as a bleb-free microporous drainage system to reduce intraocular pressure (IOP) in patients suffering from open angle glaucoma by augmenting the eye’s natural uveoscleral outflow.

Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it is estimated that 79.6 million people worldwide will have the disease. Elevated intraocular pressure is considered a major risk factor for Glaucoma and its progression.

“CE Mark approval of our first device is a major milestone,” said Michel Alvarez, CEO. He added, “We look forward to introducing STARflo to additional ophthalmologists and their patients over the coming months as we enter the post-market, limited-rollout phase for this innovative device.”

About Healionics Corporation
Healionics develops and manufactures STAR® Biomaterials for implanted medical devices. The precisely controlled pore structure of the innovative STAR technology induces a favorable integrated healing response, overcoming fibrotic reactions and infection issues to enhance medical device performance and longevity. www.healionics.com

About iSTAR Medical
iSTAR Medical SA is a Belgium-based spinout of Healionics Corporation. Its mission is to improve the lives of patients suffering from eye diseases and disorders. iSTAR’s initial focus is to develop ophthalmic implants made from STAR Biomaterial for treating glaucoma. www.istarmed.com

# # #

Contact:
Julie Rathbun
Rathbun Communications, Inc.
(206) 769-9219
Julie@rathbuncomm.com